| Biosimilar; Population | Time horizon | Projected cost savings | Additional treated patients | |
|---|---|---|---|---|
| (years) | (millions) | |||
| Ruff L, et al (2015) | ETA; RA | 5 | UK €62–162; France €19–46; Germany €42–105; Italy €26–62; Spain €16–37 | 1530 UK, 8430 Germany |
| Ruff L, et al (2015) | ETA; RA/PsA/PsO/AS | 5 | UK €111–284; France €35–81; Germany €76–187; Italy €46–111; Spain €28–65 | 3100 UK, 17130 Germany |
| Jha A, et al (2015) | IFX; RA/PsA/PsO/AS/IBD | 1 | 10%, 20% and 30% discount scenarios: €2.3, €4.6 and €6.9 in RA; €2.2, €4.3 and €6.4 in AS; €2.7, €5.3 and €8 in PsA | 10%, 20% and 30% discount scenarios: 300, 676 and 1158 in RA; 139, 313 and 538 in AS; 186, 419 and 718 in PsA |
| Brodszky V, et al (2014) | IFX; RA | 1 | €15.3 if only biologic-naive; €20.8 if also interchanging | 1205 if only biologic-naive; 1790 if also interchanging |
| Hong J, et al (2014) | IFX; RA | 5 | 10%, 20% and 30% discount scenarios: €95.9, €233 and €433.5 | NA |
| McCarthy G, et al (2013) | IFX; RA | 5 | €5.3 | 337 |
| Whitehouse J, et al (2013) | IFX; RA | 1 | €26 in France; €351 in Germany; €98 in the UK | 39% in France, 36% in Germany and 40% in the UK |
ADA: adalimumab, AS: ankylosing spondylitis, ETA: etanercept, IBD: inflammatory bowel disease, IFX: infliximab, NA: not assessed, PsA: psoriatic arthritis, PsO: psoriasis, RA: rheumatoid arthritis, UK: United Kingdom.